Clinical trials: Pemphigus Disease
Pemphigoid, Bullous, Pemphigus
Role of Proteasomes in a Dermatological Autoimmune Disease: Bullous Pemphigoid
The primary objective of this study is to describe and compare plasmatic anti-proteasome auto-antibody concentrations among three distinct groups: (1) patients suffering from bullous pemphigoide; (2) patients suffering from other…
- Conditions
- Pemphigoid, Bullous, Pemphigus, Lupus Erythematosus, Cutaneous
- Trial name
- NCT01559155
- Where
- France
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Hailey Hailey Disease
Efficacy of Guselkumab in Treating Hailey Hailey Disease
Hailey-Hailey disease (HHD) is a debilitating genetic skin disorder, affecting mainly body folds with erythema and painful erosions and blisters.
- Trial name
- NCT06651489
- Testing
- Guselkumab
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Yale University
Pemphigus
Long-term Clinical and Biological Evaluation of Patients With Severe Forms of Pemphigus Treated by Rituximab
The purpose of this study is to study the midterm clinical evaluation, biological parameters and immune reconstitution after Rituximab treatment for Pemphigus.
- Trial name
- Suiviritux (NCT01299857)
- Testing
- Rituximab
- Where
- France
- Volunteers
- 22 people
- Sponsor
- University Hospital, Rouen
Pemphigus Vulgaris
Study of Efficacy and Safety of VAY736 in Patients With Pemphigus Vulgaris
The study evaluated the efficacy, safety and pharmacokinetics of VAY736 in the treatment of patients with pemphigus vulagaris (PV).
- Trial name
- NCT01930175
- Testing
- VAY736
- Where
- 5 sites in United States, Austria and 2 more
- Volunteers
- 13 people
- Sponsor
- Novartis Pharmaceuticals
Pemphigus Disease
Comparison Between Rituximab Treatment and General Corticotherapy Treatment in Patients With Pemphigus
Pemphigus is a severe and sometimes life-threatening disease with a mortality rate between 5 and 10 percent depending on the severity of disease and age of patients.
- Trial name
- Rituximab 3 (NCT00784589)
- Testing
- General Corticotherapy, Rituximab
- Where
- France
- Volunteers
- 90 people
- Sponsor
- University Hospital, Rouen